A Double-Blind, Placebo-Controlled, Randomized To Evaluate Valbenazine For The Treatment Of Tardive Dyskinesia
Posted Date: Jun 12, 2019
- Investigator: Susan Lynn Mcelroy
- Specialties: Neurology, Neuromuscular Disorders, Psychiatry/Psychology
- Type of Study: Drug
A clinical research study for adults who have been diagnosed with schizophrenia, schizoaffective disorder, or mood disorder, and have medication-induced tardive dyskinesia. This is a 26-week clinical research study of valbenazine (or INGREZZA®). Those who qualify will receive the investigational medication, study-related medical exams, and study-related laboratory tests at no cost. Compensation for time and travel may be available. Double-blind means neither you nor the study staff, including your study doctor, will know who is taking valbenazine or placebo (or the group you are randomly assigned to). Placebo (inactive substance, like a sugar pill) is used in research studies to show what effect an investigational drug has on a subject compared with taking something that is not active. This study is being done at the Lindner Center of HOPE, located in Mason, Ohio.
Criteria:
Adults 18 To 85 Years Old Who Have Been Diagnosed With Schizophrenia, Schizoaffective Disorder, Or Mood Disorder, And Have Medication-Induced Tardive Dyskinesia
Keywords:
Tardive Dyskinesia, Valbenazine, Ingrezza
For More Information:
Brian Martens
(513) 536-0707
brian.martens@lindnercenter.org